Cellular Biomedicine Group Inc. (CBMG)’s Financial Results Comparing With AgeX Therapeutics Inc. (NYSEAMERICAN:AGE)

Since Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellular Biomedicine Group Inc. N/A 1341.58 38.95M -2.20 0.00
AgeX Therapeutics Inc. 1.54M 101.14 5.82M -0.16 0.00

Table 1 demonstrates Cellular Biomedicine Group Inc. and AgeX Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us Cellular Biomedicine Group Inc. and AgeX Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Cellular Biomedicine Group Inc. 0.00% -46.2% -43.2%
AgeX Therapeutics Inc. -377.92% 0% 0%


The current Quick Ratio of Cellular Biomedicine Group Inc. is 8.9 while its Current Ratio is 8.9. Meanwhile, AgeX Therapeutics Inc. has a Current Ratio of 6.5 while its Quick Ratio is 6.5. Cellular Biomedicine Group Inc. is better positioned to pay off its short-term and long-term debts than AgeX Therapeutics Inc.

Analyst Recommendations

In next table is given Cellular Biomedicine Group Inc. and AgeX Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellular Biomedicine Group Inc. 0 0 2 3.00
AgeX Therapeutics Inc. 0 0 0 0.00

Cellular Biomedicine Group Inc.’s upside potential is 92.19% at a $32 consensus target price.

Institutional & Insider Ownership

Institutional investors owned 19.3% of Cellular Biomedicine Group Inc. shares and 17.3% of AgeX Therapeutics Inc. shares. About 39.63% of Cellular Biomedicine Group Inc.’s share are owned by insiders. Comparatively, 45.9% are AgeX Therapeutics Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellular Biomedicine Group Inc. 4.14% 6.13% -7.28% -5.94% 11.6% 6.8%
AgeX Therapeutics Inc. -14.43% 7.24% 0% 0% 0% 38.8%

For the past year Cellular Biomedicine Group Inc.’s stock price has smaller growth than AgeX Therapeutics Inc.


AgeX Therapeutics Inc. beats Cellular Biomedicine Group Inc. on 6 of the 10 factors.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.